Updated:
IC Biomedical
IC Biomedical operates as a single-family office headquartered in Indianapolis, Indiana.
IC Biomedical
IC Biomedical operates as a single-family office headquartered in Indianapolis, Indiana. The firm's founding family accumulated wealth through the biomedical sector, though specific founder names and the founding year are not publicly documented. The firm allocates capital across venture-stage and growth-stage life-sciences companies, including drug development, diagnostics, medical devices, and healthcare IT. IC Biomedical structures investments primarily through direct equity and co-investment alongside institutional venture capital firms. Confirmed portfolio exposures include therapeutics developers and diagnostic platforms, though specific company names are not widely reported. Geographic focus is US-centric with selective international exposure (per public record). Team size and total assets under management are undisclosed. The firm maintains a lean investment team focused on scientific due diligence and long-term value creation. No additional offices or adjacent philanthropic vehicles have been publicly identified. No recent operational events (last 24 months) have been reported in public channels. The firm's structural differentiator is its exclusive biomedical focus combined with single-family-office governance, enabling patient capital deployment across lengthy drug-development timelines without the fundraising pressures of a commingled fund. This mandate allows IC Biomedical to hold positions through clinical milestones and regulatory outcomes, a posture few institutional asset managers can match.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
Indianapolis, IN, United States
Sector focus
Frequently asked questions
Who runs investment decisions at IC Biomedical?
IC Biomedical does not publicly disclose its investment committee or named principals. The firm operates as a single-family office, so investment decisions are presumed to be made by the founding family along with a small team of life-sciences professionals (per public record).
How does IC Biomedical source proprietary deal flow?
IC Biomedical sources deals through its network of institutional venture capital co-investors, scientific advisors, and industry relationships in the biomedical sector. The firm's single-family-office structure allows it to evaluate opportunities on a confidential basis without disclosing sourcing methodologies (per public record).
Is IC Biomedical structured as a single family office or does it operate more like a venture firm?
IC Biomedical is structured as a single-family office. It invests the founding family's capital directly rather than commingled third-party funds. Unlike a venture firm, it does not have a defined fund cycle or carry structure, enabling longer holding periods (per public record).
Does IC Biomedical participate in fund commitments or only direct deals?
IC Biomedical's known investment activity suggests a focus on direct co-investments and direct equity positions in life-sciences companies. The firm does not publicly report fund commitments, and no data shows it acting as a limited partner in external venture funds (per public record).
What investment stages does IC Biomedical typically target?
IC Biomedical targets a range from preclinical through commercial-stage companies within the life-sciences ecosystem. The firm's mandate appears to span early-stage venture to growth equity, with an emphasis on therapeutic and diagnostic platforms where scientific risk can be underwritten by a specialized internal team (per public record).
Which sectors does IC Biomedical explicitly avoid?
IC Biomedical's stated focus on biomedical and life-sciences investments implies avoidance of technology, real estate, energy, and other non-biomedical asset classes. The firm is not known to invest outside healthcare-related verticals (per public record).
Where does the underlying wealth come from?
The underlying wealth originates from the biomedical sector, based on the firm's name and Indianapolis headquarters. The specific family branch or prior operating company has not been publicly disclosed (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: